Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate

Scandinavian Journal of Urology and Nephrology

Volumn 43, Issue 5, 2009, Pages 377-382

  Tuncel, Altug ^a   Ener, Kemal ^a   Han, Ozge ^b   Nalcacioglu, Varol ^a   Aydin, Omur ^a   Seckin, Selda ^b   Atan, Ali ^a  

^a MINISTRY OF HEALTH   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

BPH; Dutasteride; Microvessel density; Perioperative bleeding; Serenoa repens; TURP

Indexed keywords

DUTASTERIDE; HEMOGLOBIN; PROSTAGOOD MONO; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD VOLUME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERECTILE DYSFUNCTION; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PERIOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; SABAL; STROMA; TIME; TISSUE SECTION; TRANSURETHRAL RESECTION; TREATMENT DURATION; URETHRA; WEIGHT;

AGED; AGED, 80 AND OVER; AZASTEROIDS; BLOOD LOSS, SURGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HUMANS; MALE; MICROVESSELS; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; PREOPERATIVE CARE; PROSTATE; PROSTATIC HYPERPLASIA; SERENOA; TIME FACTORS; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME;

EID: 70450194879     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365590903164498     Document Type: Article

References (27)

1. Uchida T, Ohori M, Soh S, Sato T, Iwamura M, Ao T, et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology 1999;/53:/98-105.
2. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int 1999;/83:/227-37.
3. Olsson J, Nilsson A, Hahn RG. Symptoms of the transurethral resection syndrome using glycine as the irrigant. J Urol 1995;/154:/123-8.
4. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;/141:/243-7.
5. Neal DE. The National Prostatectomy Audit. Br J Urol 1997;/79(Suppl 2):/69-75.
6. Andriole GL, Kirby R. Safety and tolerability of the 5 alpha reductase inhibitor in dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;/44:/82-8.
7. Debruyne F, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, et al. Evaluation of the clinical benefit of Permixon and Tamsulosin in severe BPH patients - Permal Study Subset Analysis. Eur Urol 2004;/45:/773-80. (Pubitemid 38638399)
8. Bayne CW, Donnelly F, Ross M. Serenoa repens: a 5-alpha reductase Tip I and II inhibitor - new evidence in a coculture model of BPH. Prostate 1999;/40:/232-41.
9. Miller MI, Puchner PJ. Effects of finasteride on haematuria associated with benign prostatic hyperplasia: long term follow-up. Urology 1998;/51:/237-40.
10. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al, for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-563
11. Sieber PR, Rommel FM, Huffnagle HW, Breslin JA, Agusta VE, Hapster LE. The treatment of gross haematuria secondary to prostatic bleeding with finasteride. J Urol 1998;/159:/1232-3.
12. Ekengren J, Hahn RG. Blood loss during transurethral resection of the prostate as measured by the hemocue photometer. Scand J Urol Nephrol 1993;/27:/501-17.
13. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006;/12:/S122-8.
14. Roehrborn CG, McNicholas T. The management of prostatic obstruction: how to determine the best options? Eur Urol 2003;/Suppl 2:/13-9.
15. Fitzpatrick JM, Mebust WK. Minimally invasive and endoscopic management of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, Kavoussi LR, Novick AC, et al, editors. Campbell's urology, vol.2. Philadelphia, PA: Saunders; . P; 2002. p. 1379-1416
16. Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;/169:/20-3.
17. Haggström S, Torring N, Moller K, Jensen E, Lund L, Nielsen JE, et al. Effects of finasteride on vascular endothelial growth factor: a placebo-controlled randomized study in BPH patients. Scand J Urol Nephrol 2002;/36:/182-7.
18. Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001;/58:/972-6.
19. Crea G, Sanfilippo G, Anastasi G, Magno C, Vizzini C, Inferrera A. Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int 2005;/74:/51-3.
20. Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002;/168:/2024-6.
21. Ozdal OL, Ozden C, Benli K, Gokkaya S, Bulut S, Memis A. Effect of short-term finasteride therapy on perioperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis 2005;/8:/215-8.
22. Lund L, Moller Ernst-Jensen K, Torring N, Nielsen JE. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol 2005;/39:/160-2.
23. Hahn RG, Fagerstrom T, Tammela TL, Vierssen Trip O, Beisland HO, Duggan A, et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int 2007; 99:587-594
24. Kirollos MM, Campbell N. Factors influencing blood loss in transurethral resection of the prostate (TURP): auditing TURP. Br J Urol 1997;/80:/111-5.
25. Marshall S, Narayan P. Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol 1993;/149:/1553.
26. Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002;/167:/1731-3.
27. Canda AE, Mungan MU, Yilmaz O, Yorukoglu K, Tuzel E, Kirkali Z. Effects of finasteride on vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. Int Urol Nephrol 2006;/ 38:/275-80.